Preliminary data from a pivotal phase III test of experimental HIV drug ibalizumab, developed by Taimed Biologics Inc. and slated for marketing by Theratechnologies Inc., helped 82.5 percent of patients receiving it meet the study's primary endpoint of a decrease of ≥ 0.5 log10 in viral load following a seven-day treatment period. Theratechnologies shares (TSX:TH) climbed 8.5 percent to close at C$2.55 (US$1.94) on Tuesday.